Search term and limits 1 (medication* adj2 review*).ti,ab 2 (drug* adj2 review*).ti,ab. 3 (prescri* adj2 review*).ti,ab 4 (medication* adj2 monitoring).ti,ab 5 (drug* adj2 monitoring).ti,ab 6 (prescri* adj2 monitoring).ti,ab 7
(medication* adj2 optimi#ation).ti,ab 8 (drug* adj2 optimi#ation).ti,ab 9
(prescri* adj2 optimi#ation).ti,ab 10 (sedative* adj2 optimi#ation).ti,ab
Proportion of participants prescribed antipsychotic drugs
Significantly lower proportion prescribed antipsychotic drugs in the medication review group compared with the non-review group at follow-up (adjusted OR b 0.17, 95% CI 0.05 to 0.60, p=0.006).
Neuropsychiatric symptoms (measured with NPI c )
Those receiving medication review had a 7.37 point (95% CI 1.53 to 13.22, p=0.02) disadvantage in NPI at follow-up compared with those not receiving review Agitation (Cohen-Mansfield Agitation Inventory)
No difference between intervention and control groups (adjusted score difference 4.60, 95% CI -1.43 to 10.63, p=0.13) Mortality
Antipsychotic review conferred a non-significant reduction in mortality compared with the group not receiving review (OR 0.67, 95% CI 0.39 to 1. 14 
Proportion of nursing home residents prescribed ≥1 inappropriate psychotropic drug at follow-up
Significantly lower proportion prescribed inappropriate psychotropic drugs in intervention group compared with the control group at followup (intervention group proportion: 20%, control group proportion: 50%, p<0.001; adjusted OR a for receiving inappropriate psychotropic medication 0.26 (0.14 to 0.49))
Rate of falls
No significant difference in rate of falls between intervention and control groups (intervention group rate: 16 
Total number of prescriptions for psychotropic medications
Reduction from 149 prescriptions at baseline to 84 prescriptions at follow-up
Average number of psychotropic prescriptions per person
Reduction from 1.86 at baseline to 1.05 at follow-up Proportion of participants with change in psychotropic drugs 47/80 (59%) changed psychotropic medication Antipsychotic polypharmacy Reduction from 4 (5%) participants at baseline to 0 (0%) participants at follow up
Reported medication side-effects
Side-effects reported in 11 (14%) participants at baseline and 8 (10%) participants at follow-up
Challenging behavior frequency counts
Reduction in the mean number of challenging behavior incidents per month Author's conclusions
The review process led to improvements in data gathering and documentation and reductions in the use of psychotropic medication use without accompanying increase in challenging behavior Source of funding 
Overall change in use of psychotropic medications
Reduction in number of medications from 496 pre-intervention to 313 post-intervention, from average of 2.4 to 1.5 per person Change in use of psychotropic medications, by type Antipsychotics: 234 prescriptions pre-intervention -83 discontinued, 101 dose reduction, 65 higher dose/initiation, 27 
Number (proportion) with change to antipsychotic drug before (without) and after (with) intervention
Greater number of participants underwent change in antipsychotic drugs occurred with the intervention (17/28) than without the intervention (11/28) Total dose of antipsychotic drugs prescribed before (without) and after (with) intervention Decrease in total dose of antipsychotic dose used with intervention
Aggressive challenging behavior
No difference in number of incidents of aggressive challenging behavior in the group undergoing intervention compared with groups not undergoing intervention Author's conclusions Multi-disciplinary medication reviews can result in reductions in the prescription of antipsychotic drugs used for challenging behavior and is not associated with worsening of aggression Source of funding Multi-disciplinary team conduct medication review according to a standard structure and provided recommendations to responsible physician. Rolling processaverage of 12 reviews per participant.
Duration of follow-up 2 years Optimisation outcome measures and results

Number (proportion) of participants with change to psychotropic medication
19/25 (76%) reduced dose 3/25 (12%) discontinued 0/25 (0%) increased dose
Number (proportion) of participants receiving psychotropic polypharmacy
Psychotropic polypharmacy: 13 (52%) before intervention, 6 (24%) at follow-up
Change in challenging behavior (frequency counts)
Average daily frequency of challenging behavior lower at the end of the program than at baseline for 20/25 participants (full data not reported) Author's conclusions Multi-disciplinary medication review is effective in reducing use of psychotropic medication in people with intellectual disabilities in a residential setting Source of funding 
